Q1: 2026-05-07 Earnings Summary
EPS of $0.32 beats by $0.41
|
Revenue of
$289.51M
(153.99% Y/Y)
misses by $18.36M
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call May 7, 2026 8:00 AM EDT
Company Participants
Chad Fugure - Vice President of Investor Relations
Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director
Scott Smith - CFO, Executive VP & Member of Executive Board
Jay Wu - Executive VP & President of Ascendis US
Conference Call Participants
Jessica Fye - JPMorgan Chase & Co, Research Division
Tazeen Ahmad - BofA Securities, Research Division
Yaron Werber - TD Cowen, Research Division
Li Wang Watsek - Cantor Fitzgerald & Co., Research Division
Patrick Culliton - Stifel, Nicolaus & Company, Incorporated, Research Division
Joseph Schwartz - Leerink Partners LLC, Research Division
Yun Zhong - Wedbush Securities Inc., Research Division
Luca Issi - RBC Capital Markets, Research Division
Selena Zhang - Morgan Stanley, Research Division
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the First Quarter Ascendis Pharma Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Chad Fugure, Vice President of Investor Relations. Please go ahead.
Chad Fugure
Vice President of Investor Relations
Thank you, operator, and thank you, everyone, for joining our first quarter 2026 financial results conference call. I'm Chad Fugure, Vice President, Investor Relations at Ascendis Pharma. Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Chief Financial Officer; Sherrie Glass, Chief Business Officer; and Jay Wu, EVP and President, U.S. Market.
Before we begin, I'd like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include, but are not limited to, statements regarding our commercialization and
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。